Skip to content
BiologicalX

Comparison

Magnesium L-Threonate vs Sermorelin

Side-by-side of Magnesium L-Threonate and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Magnesium L-Threonate

  • Distinct magnesium salt designed for blood-brain barrier penetration; not a higher-quality systemic magnesium
  • Liu 2010 rodent study: elevated CSF magnesium ~15% and increased hippocampal synaptic density
  • Trial portfolio in humans is small and mostly Magtein-funded; cognitive effects are modest where reported
  • Typical dose 1500 to 2000 mg/day delivers only ~108 to 144 mg of elemental magnesium
  • GI tolerability comparable to other magnesium forms; loose stools in a minority at 2000 mg/day
  • Distinct from magnesium glycinate, which is the conventional sleep/anxiety/repletion form

Sermorelin

  • Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
  • Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
  • Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
  • Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
  • Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
  • Banned by WADA under S2 (peptide hormones, growth factors)

Side-by-side

Attribute Magnesium L-Threonate Sermorelin
Category supplement peptide
Also known as Mg-T, MgT, Magtein, magnesium threonate Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2
Half-life (hr) 4 0.25
Typical dose (mg) 2000 0.3
Dosing frequency 1 to 3 times daily 1-2x daily
Routes oral subcutaneous
Onset (hr) 1 0.25
Peak (hr) 2 0.5
Molecular weight 294.5 3357.88
Molecular formula C8H14MgO10 C149H246N44O42S
Mechanism Proposed to deliver magnesium across the blood-brain barrier more effectively than other oral salts via threonate-related transporters, raising CNS magnesium and modulating NMDA receptor function and synaptic plasticity. Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop.
Legal status OTC dietary supplement FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA
WADA status allowed banned
DEA / Rx OTC supplement (not scheduled) Rx only via compounding (no controlled-substance schedule)
Pregnancy Standard magnesium safety; Mg-T-specific data limited Category C (historical labeling); not recommended in pregnancy
CAS 778571-57-6 86168-78-7
PubChem CID 10691810 16129617
Wikidata Q27151568 Q416620

Safety profile

Magnesium L-Threonate

Common side effects

  • loose stools
  • mild GI upset
  • headache (rare)
  • fatigue (rare)

Contraindications

  • severe renal impairment (eGFR below 30)
  • hypermagnesemia
  • myasthenia gravis (high doses)
  • concurrent IV magnesium therapy

Interactions

  • tetracyclines and fluoroquinolones: magnesium chelation reduces antibiotic absorption; separate by 2 to 4 hours(moderate)
  • bisphosphonates: reduced absorption; separate by 2 hours minimum(moderate)
  • muscle relaxants and aminoglycosides: potentiated neuromuscular blockade at high doses(moderate)
  • antihypertensives: additive blood pressure reduction at high doses(minor)

Sermorelin

Common side effects

  • injection-site pain or irritation
  • transient flushing
  • headache
  • vivid dreams (pre-bed dosing)

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • diabetic retinopathy (theoretical)
  • untreated hypothyroidism

Interactions

  • ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
  • CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: blunt GH response; reduce expected efficacy(moderate)
  • levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)

Which Should You Take?

Magnesium L-Threonate comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Sermorelin is the right call when one of the conditionals below applies.

Edge case: If you want to avoid FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA, Magnesium L-Threonate is the more accessible choice.

Default choice: Magnesium L-Threonate. Lower friction to source, and broader goal coverage. Reach for Sermorelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Magnesium L-Threonate and Sermorelin?

Magnesium L-Threonate and Sermorelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Magnesium L-Threonate or Sermorelin?

Magnesium L-Threonate half-life is 4 hours; Sermorelin half-life is 0.25 hours.

Can you stack Magnesium L-Threonate with Sermorelin?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper